07 Oct 2026, 15:25 IST
Sun Pharmaceutical Industries Limited
HDFC Securities · BUY · target Rs 2,320
The report expects 11% YoY revenue growth driven by specialty scale-up and India growth, with EBITDA margin improving on cost controls.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.